Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 36, Issue 10, 2017, Pages 1707-1709

  Giacobbe, D R ^a   Maraolo, A E ^b   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MEROPENEM; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL OUTCOME; EDITORIAL; HUMAN; INTENSIVE CARE UNIT; MONOTHERAPY; PRIORITY JOURNAL; SURVIVAL; BETA-LACTAM RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; COMBINATION DRUG THERAPY; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; MICROBIOLOGY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE INFECTIONS; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85019602786     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-017-3010-z     Document Type: Editorial

References (14)

1. Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796
2. Tumbarello M, Trecarichi EM, De Rosa FG et al (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentric study. J Antimicrob Chemother 70:2133–2143
3. Trecarichi EM, Tumbarello M (2017) Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence [Epub ahead of print]. doi:10.1080/21505594.2017.1292196
4. Papadimitriou-Olivgeris M, Fligou F, Bartzavali C et al (2017) Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality. Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-017-2899-6
5. Paul M, Carmeli Y, Durante-Mangoni E et al (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305–2309
6. Zusman O, Altunin S, Koppel F et al (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72:29–39
7. Daikos GL, Tsaousi S, Tzouvelekis LS et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328
8. Zusman O, Avni T, Leibovici L, Adler A et al (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104–5111
9. Souli M, Karaiskos I, Masgala A et al (2017) Double-carbapenem combination as salvage therapy for untreatable infections by KPC- 2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis [Epub ahead of print]. doi:10.1007/s10096-017-2936-5
10. Oliva A, Scorzolini L, Castaldi D et al (2017) Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Inf Secur 74:103–106
11. Garonzik SM, Li J, Thamlikitkul V, Paterson DL et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. 168 Antimicrob Agents Chemother 55:3284–3294
12. Del Bono V, Giacobbe DR, Marchese A et al (2017) Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 8:66–73
13. Pea F, Della Siega P, Cojutti P et al (2016) Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents 49(2):255–258
14. Sorlí L, Luque S, Segura C et al (2017) Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 17:11